Monitor the pace of ATM sales via periodic disclosures and daily volume patterns. The company's cash burn rate and Phase 3 PROACT 1 milestones (full enrollment expected Q1 2027, topline data Q2 2027) will determine how much of the facility is utilized. Any acceleration in selling could pressure the stock further.
Drug in focus
PROK drug pipeline →REACT
● Neutral Named in this 424B5- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $1.15entry
- T+1 · 4d ago −9.13%α −8.77% · $1.05
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ProKidney Corp. filed a 424B5 prospectus supplement establishing a $200 million at-the-market (ATM) equity facility with Jefferies LLC as sales agent. The company has no approved products, no revenue, and reported $141.9 million in cash as of Q3 2026, with cash runway into mid-2027. The ATM program represents potential dilution of up to 86% of current shares outstanding at the reference price of $1.13 per share, following a $650 million universal shelf filed 14 days earlier.
Key Financial Metrics
Key Facts
- ATM facility for up to $200 million of Class A common stock through Jefferies LLC
- Reference price of $1.13 per share (last reported sale on Nov 11, 2026)
- Jefferies receives commission of up to 3.0% of gross proceeds
- At the $1.13 reference price, maximum of 176,991,150 shares could be sold, representing 86% dilution from 205,716,189 shares outstanding as of June 30, 2026
- Company has no approved products, no revenue, and reported $141.9 million in cash as of Q3 2026
- Cash runway into mid-2027 per the Nov 9, 2026 8-K
- Shelf registration of $650 million (including this $200M ATM) filed Oct 29, 2026
- Net tangible book value of $222.8 million as of June 30, 2026
- Proceeds to fund clinical trials, R&D, commercial manufacturing facility, and general corporate purposes
Financial Impact
Up to $200 million in gross proceeds; maximum dilution of 86% of current shares outstanding at $1.13 per share
Risk Factors
- Massive potential dilution of up to 86% of current shares outstanding
- No approved products or revenue; pre-revenue biotech with ongoing cash burn
- ATM sales at or below the $1.13 reference price would increase dilution per dollar raised
- Short interest of ~8% of estimated shares outstanding as of Oct 30, 2026 adds selling pressure
- Multiple recent equity offerings (4 in last 24 months) signal persistent capital needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-457084 |
| Document: 0001193125-26-457084-index-headers.html | 0001193125-26-457084 |
| Document: 0001193125-26-457084-index.html | 0001193125-26-457084 |
| Document: 0001193125-26-457084.txt | 0001193125-26-457084 |
Track record
13 reports on PROK
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Viewing Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
- May 15, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers